Monitoring for adverse drug reactions
In: Proceedings of the Centre for Medicines Research Workshop [1.]1983
491562 Ergebnisse
Sortierung:
In: Proceedings of the Centre for Medicines Research Workshop [1.]1983
In: de Boer , A , van Hunsel , F & Bast , A 2015 , ' Adverse food-drug interactions ' , Regulatory Toxicology and Pharmacology , vol. 73 , no. 3 , pp. 859-865 . https://doi.org/10.1016/j.yrtph.2015.10.009
Food supplements and herbal products are increasingly popular amongst consumers. This leads to increased risks of interactions between prescribed drugs and these products containing bioactive ingredients. From 1991 up to 2014, 55 cases of suspected adverse drug reactions due to concomitant intake of health-enhancing products and drugs were reported to Lareb, the Netherlands Pharmacovigilance Centre. An overview of these suspected interactions is presented and their potential mechanisms of action are described. Mainly during the metabolism of xenobiotics and due to the pharmacodynamics effects interactions seem to occur, which may result in adverse drug reactions. Where legislation is seen to distinct food and medicine, legislation concerning these different bioactive products is less clear-cut. This can only be resolved by increasing the molecular knowledge on bioactive substances and their potential interactions. Thereby potential interactions can be better understood and prevented on an individual level. By considering the dietary pattern and use of bioactive substances with prescribed medication, both health professionals and consumers will be increasingly aware of interactions and these interactive adverse effects can be prevented.
BASE
SSRN
SSRN
In: Journal of women & aging: the multidisciplinary quarterly of psychosocial practice, theory, and research, Band 3, Heft 2, S. 85-94
ISSN: 1540-7322
In: NBER working paper series 14634
In: NBER Working Paper No. w14634
SSRN
Testimony issued by the General Accounting Office with an abstract that begins "Pursuant to a congressional request, GAO discussed its report on adverse drug events (ADE), focusing on the: (1) different types and causes of ADEs; (2) evidence on the overall incidence and cost of ADEs in the United States; and (3) measures that have been proposed to reduce the number and severity of ADEs."
BASE
In: Public Health Genomics, Band 9, Heft 1, S. 50-54
ISSN: 1662-8063
Adverse drug reactions (ADRs) are a major public health problem. Pharmacogenetic testing prior to drug treatment is supposed to considerably alleviate this problem. The state of pharmacogenetic development was assessed by a systematic literature review, supplemented by expert interviews. Analysis of three case examples revealed that – with the exception of thiopurine methyltransferase (TPMT) – studies are lacking which unambiguously prove the clinical value of pharmacogenetic testing. Testing can prevent some, but by far not all ADRs. Since it does not compensate for clinical monitoring, pharmacogenetics can be regarded as add-on technology, applied in addition to established methods. A non-representative, explorative survey conducted amongst members of the German Society of Laboratory Medicine revealed that the demand for testing is limited and has not increased much, although a certain increase is expected in the future.
Identification of adverse drug reactions (ADRs) during the post-marketing phase is one of the most important goals of drug safety surveillance. Spontaneous reporting systems (SRS) data, which are the mainstay of traditional drug safety surveillance, are used for hypothesis generation and to validate the newer approaches. The publicly available US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) data requires substantial curation before they can be used appropriately, and applying different strategies for data cleaning and normalization can have material impact on analysis results. We provide a curated and standardized version of FAERS removing duplicate case records, applying standardized vocabularies with drug names mapped to RxNorm concepts and outcomes mapped to SNOMED-CT concepts, and pre-computed summary statistics about drug-outcome relationships for general consumption. This publicly available resource, along with the source code, will accelerate drug safety research by reducing the amount of time spent performing data management on the source FAERS reports, improving the quality of the underlying data, and enabling standardized analyses using common vocabularies.
BASE
In: Bulletin of the World Health Organization: the international journal of public health = Bulletin de l'Organisation Mondiale de la Santé, Band 97, Heft 11, S. 730-730
ISSN: 1564-0604
In: Substance use & misuse: an international interdisciplinary forum, Band 32, Heft 4, S. 377-398
ISSN: 1532-2491